CAR-T Meeting 2022 | CAR-T therapy: redefining treatment options for malignant and non-malignant diseases
Raffaella Greco
• 15 Feb 2022
Raffaella Greco, MD, PhD, San Raffaele Hospital, Milan, Italy, discusses the role of chimeric antigen receptor T-cell (CAR-T) therapy in hematological malignancies and autoimmune disorders. CAR-T therapy has marked a paradigm shift in the treatment of hematological malignancies. It is now important to define the role of this new cellular therapy in the context of hematopoietic stem cell transplantation (HSCT). Similarly, CAR-Ts have recently emerged as a promising therapeutic option for patients with refractory autoimmune disorders such as systemic lupus erythematosus (SLE) who are commonly treated with HSCT. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
